{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:40:17Z","timestamp":1766428817638,"version":"3.48.0"},"reference-count":25,"publisher":"BMJ","issue":"7341","license":[{"start":{"date-parts":[[2002,4,6]],"date-time":"2002-04-06T00:00:00Z","timestamp":1018051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2001,11,8]]},"published-print":{"date-parts":[[2002,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To assess the cost effectiveness of a meningococcal serogroup C conjugate vaccination campaign in 0-17 year olds.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design:<\/jats:bold>\n                    Cost effectiveness analysis from the perspective of the healthcare provider.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting:<\/jats:bold>\n                    England and Wales.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measure:<\/jats:bold>\n                    Cost per life year saved.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In 1998-9, immediately before the introduction of meningococcal C vaccination, the burden of serogroup C disease was considerable, with an estimated 1137 cases in people aged 0-17 years and at least 72 deaths. The vaccination campaign is estimated to have cost between \u00a3126m ($180m, \u20ac207m) and \u00a3241m ($343m, \u20ac395m), depending on the price of the vaccine. Under base case assumptions the cost per life year saved from the vaccination campaign is estimated to be \u00a36259. School based vaccination was more cost effective than general practice based vaccination because of lower delivery costs. Immunisation of infants aged under 1 year was the least cost effective component of the campaign because, although this maximises the life years gained, the three dose schedule required is more expensive than other methods of delivery. Estimates of the cost per life year saved were sensitive to assumptions on the future incidence of disease and the case fatality ratio.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Meningococcal C vaccination is likely to be more cost effective in all age groups when the incidence of disease is high. It is also more cost effective when given to children aged 1-4 (by general practitioners) and to children and young people aged 5-17 years at school than when administered to infants under 12 months of age or young people aged 16-17 years who are not at school.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text id=\"FB1\" position=\"float\">\n                      <jats:sec>\n                        <jats:title>What is already known on this topic<\/jats:title>\n                        <jats:p>The burden of group C meningococcal disease in England and Wales in the late 1990s was considerable<\/jats:p>\n                        <jats:p>In November 1999 the United Kingdom was the first country to introduce mass vaccination against group C meningococcal disease<\/jats:p>\n                        <jats:p>There are no published economic evaluations of the vaccination campaign<\/jats:p>\n                      <\/jats:sec>\n                      <jats:sec>\n                        <jats:title>What this study adds<\/jats:title>\n                        <jats:p>This economic evaluation supports the introduction of the meningococcal C vaccine<\/jats:p>\n                        <jats:p>School based vaccination is more cost effective than routine vaccination of infants because delivery costs are lower and fewer doses are required<\/jats:p>\n                      <\/jats:sec>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1136\/bmj.324.7341.809","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:45:32Z","timestamp":1027752332000},"page":"809","source":"Crossref","is-referenced-by-count":65,"title":["Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales"],"prefix":"10.1136","volume":"324","author":[{"given":"Caroline L","family":"Trotter","sequence":"first","affiliation":[{"name":"Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W John","family":"Edmunds","sequence":"additional","affiliation":[{"name":"Department of Economics, City University, London EC1V 0HB"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2002,4,6]]},"reference":[{"key":"2025122121214066000_324.7341.809.1","unstructured":"Chief Medical Officer, Chief Nursing Officer, and Chief Pharmacist .Introduction of immunisation against group C meningococcal infection. London:Department of Health,1999 (PL\/CMO\/99\/02)."},{"key":"2025122121214066000_324.7341.809.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00299-7"},{"key":"2025122121214066000_324.7341.809.3","doi-asserted-by":"publisher","DOI":"10.1086\/314753"},{"key":"2025122121214066000_324.7341.809.4","unstructured":"Begg N .Outbreak management. In: Cartwright K , ed. Meningococcal disease. Chichester:Wiley,1995:285\u2013305."},{"key":"2025122121214066000_324.7341.809.5","doi-asserted-by":"crossref","unstructured":"Gold MR Siegel JE Russell LB Weinstein MC .Cost-effectiveness in health and medicine. Oxford:Oxford University Press,1996.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2025122121214066000_324.7341.809.6","unstructured":"Department of Health .Policy appraisal and health. London:Department of Health,1995."},{"key":"2025122121214066000_324.7341.809.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/esm.02.10.00147-en","article-title":"The epidemiology of meningococcal disease in England and Wales, 1996 and 1997.","volume":"2","author":"Ramsay","year":"1997","journal-title":"Eurosurveillance"},{"key":"2025122121214066000_324.7341.809.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7111.774"},{"key":"2025122121214066000_324.7341.809.9","unstructured":"Netten A Curtis L .Unit costs of health and social care 2000. Canterbury:Personal Social Services Research Unit, University of Kent,2000."},{"key":"2025122121214066000_324.7341.809.10","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199305000-00008"},{"key":"2025122121214066000_324.7341.809.11","doi-asserted-by":"publisher","DOI":"10.1086\/520303"},{"key":"2025122121214066000_324.7341.809.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.19.2329"},{"key":"2025122121214066000_324.7341.809.13","doi-asserted-by":"publisher","DOI":"10.3109\/00365549609027149"},{"key":"2025122121214066000_324.7341.809.14","first-page":"R3","article-title":"Management of clusters of meningococcal disease.","volume":"7","author":"Stuart","year":"1997","journal-title":"Commun Dis Rep CDR Rev"},{"key":"2025122121214066000_324.7341.809.15","unstructured":"British Medical Association, Royal Pharmaceutical Society of Great Britain .British National Formulary 39. London:BMA, Royal Pharmaceutical Society of Great Britain,2000."},{"key":"2025122121214066000_324.7341.809.16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/oxfordjournals.pubmed.a024604","article-title":"Community immunization programme in response to an outbreak of invasive Neisseria meningitidis serogroup C infection in the Trent region of England 1995-1996.","volume":"19","author":"Irwin","year":"1997","journal-title":"J Public Health Med"},{"key":"2025122121214066000_324.7341.809.17","first-page":"168","article-title":"Practical guidelines for responding to an outbreak of meningococcal disease among university students based on experience in Southampton.","volume":"2","author":"Barker","year":"1999","journal-title":"Commun Dis Public Health"},{"key":"2025122121214066000_324.7341.809.18","first-page":"297","article-title":"Meningococcal disease in Ironville.","volume":"9","year":"1999","journal-title":"Commun Dis Rep CDR Wkly"},{"key":"2025122121214066000_324.7341.809.19","first-page":"311","article-title":"Outbreak of meningococcal disease in students in Cardiff.","volume":"6","year":"1996","journal-title":"Commun Dis Rep CDR Wkly"},{"key":"2025122121214066000_324.7341.809.20","first-page":"393","article-title":"cLUSTers of meningococcal disease in university students.","volume":"7","year":"1997","journal-title":"Commun Dis Rep CDR Wkly"},{"key":"2025122121214066000_324.7341.809.21","unstructured":"Anon .Meningococcal disease [replacement chapter. In: Salisbury DM Begg NT , eds. Immunisation against infectious disease. London:HMSO,1999."},{"key":"2025122121214066000_324.7341.809.22","first-page":"14","article-title":"Safety of meningococcal group C conjugate vaccines.","volume":"26","year":"2000","journal-title":"Current Problems in Pharmacovigilance"},{"key":"2025122121214066000_324.7341.809.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03594-7"},{"key":"2025122121214066000_324.7341.809.24","unstructured":"CDSC .COVER programme: April to June 2001. Commun Dis Rep Weekly [serial online] 2001; 11:immunisation. www.phls.org.uk\/publications\/CDR%20Weekly\/archive\/immunisationarchive.html (accessed Feb 2002)."},{"key":"2025122121214066000_324.7341.809.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.1.93"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.324.7341.809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.324.7341.809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:21:51Z","timestamp":1766380911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.324.7341.809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,6]]},"references-count":25,"journal-issue":{"issue":"7341","published-online":{"date-parts":[[2002,4,6]]},"published-print":{"date-parts":[[2002,4,6]]}},"alternative-id":["10.1136\/bmj.324.7341.809"],"URL":"https:\/\/doi.org\/10.1136\/bmj.324.7341.809","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1756-1833"}],"subject":[],"published":{"date-parts":[[2002,4,6]]}}}